Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Research

• Publication date

  2010-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-09-4524PMID 20484037PMCID PMC2895805
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The hallmarks of cancer

  2012cited by this paper
• Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.

  2009cited by this paper
• A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer

  2009cited by this paper
• High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

  2009cited by this paper
• In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

  2009cited by this paper
• Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

  2008cited by this paper
• ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

  2008influential reference
• Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

  2008cited by this paper
• IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a (PII:S0092-8674(04)00302-2)

  2007cited by this paper
• The emerging roles of forkhead box (Fox) proteins in cancer

  2007cited by this paper
• AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

  2007cited by this paper
• Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines

  2007cited by this paper
• BRAF mutation predicts sensitivity to MEK inhibition

  2006cited by this paper
• FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer.

  2006cited by this paper
• Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer.

  2006cited by this paper
• Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.

  2006cited by this paper
• Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization.

  2005cited by this paper
• Effects of active MEK1 expression in vivo.

  2005cited by this paper
• Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

  2005cited by this paper
• Coordinating ERK/MAPK signalling through scaffolds and inhibitors

  2005cited by this paper
• Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt

  2004cited by this paper
• IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a.

  2004cited by this paper
• Cancer genes and the pathways they control

  2004cited by this paper
• FoxO3a Transcriptional Regulation of Bim Controls Apoptosis in Paclitaxel-treated Breast Cancer Cell Lines*

  2003cited by this paper
• Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

  1999cited by this paper
• ras Oncogenes and the molecular mechanisms of carcinogenesis.

  1984cited by this paper

• Microbiome in radiotherapy: an emerging approach to enhance treatment efficacy and reduce tissue injury

  2024cites this paper
• Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

  2023cites this paper
• The discrete roles of individual FOXO transcription factor family members in B-cell malignancies

  2023cites this paper
• The Role of microRNA-23a-3p in the Progression of Human Aging Process by Targeting FOXO3a

  2023cites this paper
• FOXO3a in cancer drug resistance.

  2022cites this paper
• Regulation of radiation‐induced liver damage by modulation of SIRT‐1 activity: In vivo rat model

  2022cites this paper
• ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer

  2021cites this paper
• Role of Forkhead Box O Proteins in Hepatocellular Carcinoma Biology and Progression (Review)

  2021cites this paper
• Oxidative Stress and Aging : Changes in Important Cell Signaling Pathways

  2021cites this paper
• Target identification for small-molecule discovery in the FOXO3a tumor-suppressor pathway using a biodiverse peptide library

  2021cites this paper
• Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer

  2020cites this paper
• Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patient-derived organoids

  2020cites this paper
• Transcriptional regulators and alterations that drive melanoma initiation and progression

  2020cites this paper
• The role of different SIRT1-mediated signaling pathways in toxic injury

  2019cites this paper
• Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation

  2019cites this paper
• Forkhead box O3 promotes colon cancer proliferation and drug resistance by activating MDR1 expression

  2019cites this paper
• FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway.

  2019cites this paper
• Circ-Foxo3 is positively associated with the Foxo3 gene and leads to better prognosis of acute myeloid leukemia patients

  2019cites this paper
• Sulfonylurea derivatives and cancer, friend or foe?

  2019influential citation
• SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC

  2019cites this paper
• Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma

  2017cites this paper
• Bim may be a poor prognostic biomarker in breast cancer patients especially in those with luminal A tumors

  2017cites this paper
• The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance

  2017cites this paper
• Targeting miR-155 inhibits survival of melanoma cells by upregulating FOXO 3 a

  2017cites this paper
• FoxO3a mediates glioma cell invasion by regulating MMP9 expression.

  2016cites this paper
• Diversity and implication of MAPK signal transduction involved in the regulation of chemotherapy-induced DNA damage response

  2016cites this paper
• Increased phosphorylation of ERK1/2 is associated with worse chemotherapeutic outcome and a poor prognosis in advanced lung adenocarcinoma

  2016cites this paper
• PTEN-regulated AKT/FoxO3a/Bim signaling contributes to Human cell glioblastoma apoptosis by platinum-maurocalcin conjugate.

  2016cites this paper
• A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer

  2016cites this paper
• The Role of FOXO3 in Mechanisms of Doxorubicin Resistance in Hepatocellular Carcinoma

  2016cites this paper
• Differential Cytotoxic Effects of Jaspine B in Various Cancer Cells

  2016cites this paper
• Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review

  2015cites this paper
• ANALYSIS OF IMMUNOREGULATORY BIOMARKERS IN NON-SMALL CELL LUNG CANCER

  2015cites this paper
• The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism*

  2015cites this paper
• Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo

  2015cites this paper
• BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

  2015cites this paper
• FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells

  2014cites this paper
• KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

  2014cites this paper
• FoxO proteins: regulation and molecular targets in liver cancer.

  2014cites this paper
• Signaling cross-talk in the resistance to HER family receptor targeted therapy

  2014cites this paper
• MicroRNA-96 inhibits FoxO3a function in IPF fibroblasts on type I collagen matrix.

  2014cites this paper
• Resistance to Selumetinib (AZD6244) in Colorectal Cancer Cell Lines is Mediated by p70S6K and RPS6 Activation1

  2014cites this paper
• FoxO3a and disease progression.

  2014cites this paper
• Bi-directional signaling between melanoma and the microenvironment generates a protective niche that mediates therapeutic escape

  2014cites this paper
• BH3-only蛋白在非小细胞肺癌靶向治疗中的作用及意义

  2014cites this paper
• FoxO3a and disease progression World Journal of Biological Chemistry

  2014cites this paper
• Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

  2013cites this paper
• Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma

  2013cites this paper
• CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.

  2013cites this paper
• Translocation , TRAIL Gene Induction , and Potent Antitumor Effects Dual Inactivation of Akt and ERK by TIC 10 Signals Foxo 3 a Nuclear

  2013cites this paper
• Signaling by the phosphoinositide 3-kinase family in immune cells.

  2013cites this paper
• Acquired resistance to targeted MAPK inhibition in melanoma

  2013influential citation
• Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia

  2013cites this paper
• Growth Factor Receptor Signaling, DNA Damage Response, and Cancer Cell Susceptibility to Chemotherapy and Relapses

  2013cites this paper
• Genetics and biomarkers in personalisation of lung cancer treatment.

  2013cites this paper
• T 63 , a new 4-arylidene curcumin analogue , induces cell cycle arrest and apoptosis through activation of the reactive oxygen species – FOXO 3 a pathway in lung cancer cells

  2012cites this paper
• Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer

  2012cites this paper
• Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion

  2012cites this paper
• T63, a new 4-arylidene curcumin analogue, induces cell cycle arrest and apoptosis through activation of the reactive oxygen species-FOXO3a pathway in lung cancer cells.

  2012cites this paper
• Inhibition of metadherin sensitizes breast cancer cells to AZD6244

  2012influential citation
• Pachastrissamine from Pachastrissa sp. Inhibits Melanoma Cell Growth by Dual Inhibition of Cdk2 and ERK‐mediated FOXO3 Downregulation

  2012cites this paper
• Análise citogenética e molecular do gene FOXO3 em síndrome mielodisplásica

  2011cites this paper
• Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

  2011cites this paper
• Melanoma Cell Signalling: Looking Beyond RAS-RAF-MEK

  2011cites this paper
• Deciphering the role of forkhead transcription factors in cancer therapy.

  2011cites this paper
• Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells

  2011cites this paper
• The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment.

  2011cites this paper
• Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.

  2011cites this paper
• Knockdown of FLOT1 Impairs Cell Proliferation and Tumorigenicity in Breast Cancer through Upregulation of FOXO3a

  2011cites this paper
• Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer

  2011influential citation
• Targeted therapy of obesity-associated colon cancer

  2011cites this paper
• Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim

  2010cites this paper
• Unregulated miR-96 Induces Cell Proliferation in Human Breast Cancer by Downregulating Transcriptional Factor FOXO3a

  2010cites this paper
• MEK/MAPK inhibitors.

  2010cites this paper
• Poly(ADP-Ribose) Polymerase Inhibitors

  2010cites this paper